
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : SGX-001
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Vi Partners
Deal Size : $11.6 million
Deal Type : Series A Financing
Somagenetix Secures CHF 10M to Advance Gene Therapy For CGD
Details : The funds will enable Somagenetix to advance its leading gene therapy-candidate, SGX-001, into a clinical trial for the treatment of p47 Chronic Granulomatous Disease (CGD).
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
October 08, 2024
Lead Product(s) : SGX-001
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Vi Partners
Deal Size : $11.6 million
Deal Type : Series A Financing
